IP Library Granted Patent US 6,956,111
Granted Patent B2
US 6,956,111 · App. 09/796,807 · Granted Oct 18, 2005

Method of determining dihydropyrimidine dehydrogenase gene expression

Assignee: Response Genetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,956,111
App. No.
09/796,807
Granted
Oct 18, 2005
Kind
B2
Abstract

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing Dihydropyrimidine dehydrogenase (DPD) expression levels in tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU based therapies by examination of the amount of DPD mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pairs DPD3A and DPD3B and methods comprising their use for detecting levels of Dihydropyrimidine dehydrogenase (DPD) mRNA.

Claims (6)

1. An isolated and purified oligonucleotide consisting of the sequence of SEQ ID NO: 1; wherein said isolated and purified oligonucleotide is capable of amplifying a portion of the 5′ untranslated region and Exon 1 of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 2.

2. An isolated and purified oligonucleotide consisting of the sequence of SEQ ID NO: 2; wherein said isolated and purified oligonucleotide is capable of amplifying a portion of the 5′ untranslated region and Exon 1 of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 1.

3. An isolated and purified oligonucleotide consisting of the sequence of SEQ ID NO: 7; wherein said isolated and purified oligonucleotide is capable of amplifying a portion of Exon 6 of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 8.

4. An isolated and purified oligonucleotide consisting of the sequence of SEQ ID NO: 8; wherein said isolated and purified oligonucleotide is capable of amplifying a portion of Exon 6 of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 7.

5. A kit for detecting expression of a Dihydropyrimidine Dehydrogenase (DPD) gene in a tissue comprising at least two oligonucleotide primers, said two oligonucleotide primers consisting of SEQ ID NO: 1; capable of amplifying a portion of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO:2; and SEQ ID NO: 2; capable of amplifying a portion of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 1.

6. A kit for detecting expression of a Dihydropyrimidine Dehydrogenase (DPD) gene in a tissue comprising at least two oligonucleotide primers, said two oligonucleotide primers consisting of SEQ ID NO:7 capable of amplifying portion of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 8; and SEQ ID NO: 8; capable of amplifying a portion of a Dihydropyrimidine Dehydrogenase (DPD) mRNA isolated from fixed and paraffin embedded (FPE) tumor tissue when used with SEQ ID NO: 7.

Assignments (6)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 16, 2019
From: PARTNERS FOR GROWTH IV, L.P.
To: CANCER GENETICS, INC.
Reel/Frame 049771/0446 →
FIRST AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 21, 2017
From: CANCER GENETICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 042928/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: RESPONSE GENETICS, INC.
To: CANCER GENETICS, INC.
Reel/Frame 042257/0576 →
SECURITY INTEREST Recorded May 1, 2017
From: CANCER GENETICS, INC.
To: PARTNERS FOR GROWTH V, L.P.
Reel/Frame 042192/0126 →
SECURITY INTEREST Recorded Jan 29, 2015
From: RESPONSE GENETICS, INC.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 034848/0647 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2001
From: DANENBERG, KATHLEEN
To: RESPONSE GENETICS, INC.
Reel/Frame 012086/0487 →
Continuity (1)
Related Publication 20020123620A1 · Sep 5, 2002